BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8209612)

  • 1. [Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia].
    Wysocki M; Kurylak A; Pilecki O; Balcar-Boroń A
    Acta Haematol Pol; 1994; 25(1):37-42. PubMed ID: 8209612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases].
    Jouet JP; Simon M; Fenaux P; Pollet JP; Bauters F
    Nouv Rev Fr Hematol (1978); 1985; 27(3):169-73. PubMed ID: 3862072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia.
    Wysocki M; Nowaczyk-Michalak A; Pilecki O; Trybuś L; Balcar-Boroń A
    Acta Haematol Pol; 1992; 23(3):197-9. PubMed ID: 1492544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.